Thursday, January 6, 2022

ONK Therapeutics Snags $21.5M for NK Cell Therapies

San Diego- and Galway, Ireland-based ONK Therapeutics announced today that it has raised $21.5M in its Series A funding. The funding was led by Acorn Bioventures and ALSHC, plus Cormorant Asset Management. The startup says it is developing optimally engineered natural killer (NK) cell therapies. ONK said the new funding will go to drive multiple

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.